Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With TezepelumabNot Yet Recruiting
NCT07013123Phase 3Updated Jun 10, 2025
Sponsor: University Hospital, Montpellier
Severe Asthma · Allergy to House Dust Mites
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004Completed
NCT06742762Phase 1Updated Jun 8, 2025
Sponsor: AstraZeneca
Renal Impairment
United States
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response StudyCompleted
NCT05872958Phase 1Updated Jun 6, 2025
Sponsor: AstraZeneca
COVID-19
United States
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)Completed
NCT05465213N/AUpdated Jun 6, 2025
Sponsor: AstraZeneca
Heart Failure
Portugal
A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy AdultsCompleted
NCT06723756Phase 1Updated Jun 5, 2025
Sponsor: AstraZeneca
Healthy Participants
United States
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.Completed
NCT06732882Phase 1Updated Jun 5, 2025
Sponsor: AstraZeneca
Asthma
Germany, United Kingdom
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawn
NCT06839872Phase 2Updated Jun 5, 2025
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruiting
NCT06880354Phase 1Updated Jun 3, 2025
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
China
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminated
NCT04189952Phase 2Updated May 31, 2025
Sponsor: University of Miami
Diffuse Large B Cell Lymphoma · Chronic Lymphocytic Leukemia · Small Lymphocytic Leukemia · Marginal Zone Lymphoma
United States
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.Completed
NCT06494644Phase 1Updated May 31, 2025
Sponsor: AstraZeneca
Healthy Participants
Germany
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminated
NCT03277482Phase 1Updated May 31, 2025
Sponsor: Dana-Farber Cancer Institute
Recurrent Gynecological Cancer · Metastatic Cervical Cancer · Metastatic Ovarian Cancer · Metastatic Vaginal Cancer
United States
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminated
NCT03505710Phase 2Updated May 30, 2025
Sponsor: Daiichi Sankyo
Non-Small Cell Lung Cancer
United States, France, Japan, Netherlands, Spain
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in SpainRecruiting
NCT06991946N/AUpdated May 28, 2025
Sponsor: SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
Spain
A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004Completed
NCT06857695Phase 1Updated May 28, 2025
Sponsor: AstraZeneca
Healthy Participants
United Kingdom
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCTerminated
NCT04441138Phase 2Updated May 28, 2025
Sponsor: Rush University Medical Center
Stage III Non-small-cell Lung Cancer
United States
hATTR Polyneuropathy in RussiaCompleted
NCT06365593N/AUpdated May 25, 2025
Sponsor: AstraZeneca
Hereditary Transthyretin Amyloidosis
Russia
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerCompleted
NCT04774380Phase 3Updated May 23, 2025
Sponsor: AstraZeneca
Extensive-stage Small Cell Lung Cancer
Bulgaria, Canada, Czechia, Germany, Italy +1 more
Prospective Tissue Collection Research ProtocolCompleted
NCT03517917N/AUpdated May 23, 2025
Sponsor: AstraZeneca
Solid Tumor
United States, Spain, United Kingdom
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompleted
NCT05958134N/AUpdated May 23, 2025
Sponsor: AstraZeneca
Diffuse Large B Cell Lymphoma
Brazil
Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin AloneCompleted
NCT04090580Phase 3Updated May 22, 2025
Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type 2 Diabetes
Mexico
MEOI and HRQoL in CLL Patients Treated With BTKisCompleted
NCT04938141N/AUpdated May 21, 2025
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
United States
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney DiseaseCompleted
NCT05432167Phase 2Updated May 20, 2025
Sponsor: AstraZeneca
Uncontrolled Hypertension · Chronic Kidney Diseases
United States
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling By Invitation
NCT06419179Phase 2Updated May 20, 2025
Sponsor: University of Cologne
Small Cell Lung Carcinoma
Germany
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney DiseaseEnrolling By Invitation
NCT06330480NAUpdated May 16, 2025
Sponsor: Prof. Dr. Folkert W. Asselbergs
Atrial Fibrillation · Chronic Kidney Diseases · Diabetes Mellitus, Type 2
Netherlands
Heart Failure Patients RegistryCompleted
NCT04709263N/AUpdated May 15, 2025
Sponsor: AstraZeneca
Heart Failure
Russia

Previous page Next page